Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 58

1.

Lipid phosphatases as a possible therapeutic target in cases of type 2 diabetes and obesity.

Sasaoka T, Wada T, Tsuneki H.

Pharmacol Ther. 2006 Dec;112(3):799-809. Epub 2006 Jul 13. Review.

PMID:
16842857
2.
3.

Lipid phosphatases as drug discovery targets for type 2 diabetes.

Lazar DF, Saltiel AR.

Nat Rev Drug Discov. 2006 Apr;5(4):333-42. Review.

PMID:
16582877
4.

The SH2 domain containing inositol polyphosphate 5-phosphatase-2: SHIP2.

Dyson JM, Kong AM, Wiradjaja F, Astle MV, Gurung R, Mitchell CA.

Int J Biochem Cell Biol. 2005 Nov;37(11):2260-5. Review.

PMID:
15964236
5.

SHIP2: an emerging target for the treatment of type 2 diabetes mellitus.

Baumgartener JW.

Curr Drug Targets Immune Endocr Metabol Disord. 2003 Dec;3(4):291-8. Review.

PMID:
14683460
6.

Phosphoinositide phosphatases: just as important as the kinases.

Dyson JM, Fedele CG, Davies EM, Becanovic J, Mitchell CA.

Subcell Biochem. 2012;58:215-79. doi: 10.1007/978-94-007-3012-0_7. Review.

PMID:
22403078
7.

The role of the inositol polyphosphate 5-phosphatases in cellular function and human disease.

Ooms LM, Horan KA, Rahman P, Seaton G, Gurung R, Kethesparan DS, Mitchell CA.

Biochem J. 2009 Apr 1;419(1):29-49. doi: 10.1042/BJ20081673. Review.

PMID:
19272022
8.

PTEN and SHIP2 phosphoinositide phosphatases as negative regulators of insulin signalling.

Vinciguerra M, Foti M.

Arch Physiol Biochem. 2006 Apr;112(2):89-104. Review.

PMID:
16931451
9.

SHIP2 and its involvement in various diseases.

Suwa A, Kurama T, Shimokawa T.

Expert Opin Ther Targets. 2010 Jul;14(7):727-37. doi: 10.1517/14728222.2010.492780. Review.

PMID:
20536411
10.

SHIP2 multiple functions: a balance between a negative control of PtdIns(3,4,5)P₃ level, a positive control of PtdIns(3,4)P₂ production, and intrinsic docking properties.

Erneux C, Edimo WE, Deneubourg L, Pirson I.

J Cell Biochem. 2011 Sep;112(9):2203-9. doi: 10.1002/jcb.23146. Review.

PMID:
21503961
11.

The termination of PI3K signalling by SHIP1 and SHIP2 inositol 5-phosphatases.

Backers K, Blero D, Paternotte N, Zhang J, Erneux C.

Adv Enzyme Regul. 2003;43:15-28. Review. No abstract available.

PMID:
12791379
12.

The role of SHIP in cytokine-induced signaling.

Kalesnikoff J, Sly LM, Hughes MR, Büchse T, Rauh MJ, Cao LP, Lam V, Mui A, Huber M, Krystal G.

Rev Physiol Biochem Pharmacol. 2003;149:87-103. Epub 2003 Apr 12. Review.

PMID:
12692707
13.

Insulin-sensitive protein kinases (atypical protein kinase C and protein kinase B/Akt): actions and defects in obesity and type II diabetes.

Farese RV, Sajan MP, Standaert ML.

Exp Biol Med (Maywood). 2005 Oct;230(9):593-605. Review.

PMID:
16179727
14.

Antagonism of PI 3-kinase-dependent signalling pathways by the tumour suppressor protein, PTEN.

Downes CP, Bennett D, McConnachie G, Leslie NR, Pass I, MacPhee C, Patel L, Gray A.

Biochem Soc Trans. 2001 Nov;29(Pt 6):846-51. Review.

PMID:
11709086
15.

PTEN, Insulin Resistance and Cancer.

Li A, Qiu M, Zhou H, Wang T, Guo W.

Curr Pharm Des. 2017;23(25):3667-3676. doi: 10.2174/1381612823666170704124611. Review.

PMID:
28677502
16.
17.
18.

Phosphoinositide signaling disorders in human diseases.

Pendaries C, Tronchère H, Plantavid M, Payrastre B.

FEBS Lett. 2003 Jul 3;546(1):25-31. Review.

19.

Inhibition of protein tyrosine phosphatase 1B as a potential treatment of diabetes and obesity.

Pei Z, Liu G, Lubben TH, Szczepankiewicz BG.

Curr Pharm Des. 2004;10(28):3481-504. Review.

PMID:
15579047
20.

[SHIP2 down-regulates insulin sensitivity via inhibiting PI3-K/Akt signaling].

Zou L, Li FQ.

Sheng Li Ke Xue Jin Zhan. 2010 Feb;41(1):62-4. Review. Chinese. No abstract available.

PMID:
21417020

Supplemental Content

Support Center